Listen on the go
CORRECT!
Next question
touchNEUROLOGY touchNEUROLOGY
Multiple Sclerosis
Watch Time: 5 mins

Dominic Shadbolt: ECTRIMS Patient perspective – Technologies and tools to predict patient outcomes in MS

Copy Link
Published Online: Nov 18th 2022

We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights new technologies and tools in predicting patient outcomes.

Interviews in this series:

ECTRIMS Patient perspective highlights – The importance of early intervention in MS

ECTRIMS Patient perspective highlights – Technologies and tools to predict patient outcomes

ECTRIMS Patient perspective highlights – Lifestyle interventions as part of a management plan for MS

Disclosures: Dominic Shadbolt has nothing to disclose in relation to this interview.

Support:

Touch Medical Media made a donation to a charity of the speaker’s choice, Shift.ms, to support this video interview.

Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of ECTRIMS 2022

Access more content on MS here

Share this Video
Related Videos In Multiple Sclerosis
Multiple Sclerosis
Developed by Touch
Simon Faissner, EAN 2023: Safety and efficacy of diroximel fumarate in older patients with multiple sclerosis from the phase III EVOLVE-MS-1 study
Watch Time: 6 mins

Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]

Multiple Sclerosis
Developed by Touch
Enrique Alvarez, AAN 2023: Disease outcomes with ublituximab in participants with highly active disease from subpopulation analyses of the phase III ULTIMATE I and II studies in participants with relapsing multiple sclerosis
Watch Time: 06:32

The phase III clinical studies Ultimate I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the aim, designs and outcomes of these studies as well as the subpopulation analyses […]

Multiple Sclerosis
Developed by Touch
Enrique Alvarez, AAN 2023: Ublituximab for participants with relapsing multiple sclerosis
Watch Time: 0:56

The phase III clinical studies ULTIMATE I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the unmet needs of this population and the mechanism of action of ublituximab. The […]

Trending In Multiple Sclerosis:

Simon Faissner, EAN 2023: Safety and efficacy of diroximel fumarate in older patients with multiple sclerosis from the phase III EVOLVE-MS-1 study
Multiple Sclerosis
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32 social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72